Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share news the company has announced the beginning of a Phase II open-label pilot study which will investigate the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis. Elsley telling Proactive study will evaluate the use of CardiolRx as a novel therapy for pericarditis. The study is expected to enroll 25 patients at clinical centers in the United States that specialize in pericarditis care.
Cardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent Pericarditis
